Provention bio announces positive final results from first-in-human study of coxsackievirus b vaccine candidate prv-101

Prv-101 continued to be well tolerated and elicited durable high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers red bank, n.j. , march 28, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced positive results from the final analysis of its first-in-human provent study of prv-101, a polyvalent inactivated coxsackievirus b (cvb) vaccine candidate targeting all key cvb strains associated with type 1 diabetes (t1d) autoimmunity.
PRVB Ratings Summary
PRVB Quant Ranking